Experience of Rituximab Treatment in Two Patients with Severe Systemic Lupus Erythematosus / 대한류마티스학회지
The Journal of the Korean Rheumatism Association
;
: 230-235, 2006.
Artigo
em Coreano
| WPRIM
| ID: wpr-34695
ABSTRACT
Rituximab is a chimeric monoclonal antibody for human B lymphocyte subset CD20 and has recently been used for treatment of autoimmune disease such as rheumatoid arthritis and systemic lupus erythematosus (SLE). We report the experiences of rituximab treatment in two patients with severe SLE. The first case is 16-year-old female patient with hemolytic anemia, thrombocytopenia and acute renal failure due to aggravation of lupus nephritis, and the second case is 30-year-old female pregnant patient with diffuse alveolar hemorrhage after preterm premature rupture of fetal membranes. All two patients responded to rituximab and maintained symptom free state.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Artrite Reumatoide
/
Doenças Autoimunes
/
Trombocitopenia
/
Nefrite Lúpica
/
Ruptura Prematura de Membranas Fetais
/
Subpopulações de Linfócitos
/
Injúria Renal Aguda
/
Rituximab
/
Hemorragia
/
Anemia Hemolítica
Limite:
Adolescente
/
Adulto
/
Feminino
/
Humanos
/
Gravidez
Idioma:
Coreano
Revista:
The Journal of the Korean Rheumatism Association
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS